InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Aligos Therapeutics, Inc.

ALGS Clue Score31
United States Fiscal year ends December CIK 0001799448
$5.34 +0.56% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $5.34 −60.59% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Oct 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−54.0Net income−52.3Fiscal year 2020Revenue0.0Operating income−97.8Net income−108.5Fiscal year 2021Revenue0.0Operating income−128.3Net income−128.3Fiscal year 2022Revenue0.0Operating income−97.6Net income−96.0EPS, diluted−2.25Fiscal year 2023Revenue6.2Operating income−88.1Net income−87.7EPS, diluted−34.20Fiscal year 2024Revenue3.6 −41.7%Operating income−89.2Net income−131.2EPS, diluted−20.94Fiscal year 2025Revenue2.2 −39.5%Operating income−88.0Net income−24.2EPS, diluted−2.45
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a 0.0 0.0 0.0 6.2 3.6 2.2
Growth −41.7% −39.5%
Operating income −54.0 −97.8 −128.3 −97.6 −88.1 −89.2 −88.0
Net income −52.3 −108.5 −128.3 −96.0 −87.7 −131.2 −24.2
Growth
EPS, diluted n/a n/a n/a −2.25 −34.20 −20.94 −2.45

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Operating margin−1,423.5%Net margin−1,416.2%Free cash flow margin−1,276.3%Fiscal year 2024Operating margin−2,469.0%Net margin−3,633.6%Free cash flow margin−2,239.6%Fiscal year 2025Operating margin−4,024.9%Net margin−1,106.7%
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −1,423.5% −2,469.0% −4,024.9%
Net margin n/a n/a n/a n/a −1,416.2% −3,633.6% −1,106.7%
Free cash flow margin n/a n/a n/a n/a −1,276.3% −2,239.6% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−46.8Capital expenditure−2.8Free cash flow−49.6Fiscal year 2020Operating cash flow−74.3Capital expenditure−2.1Free cash flow−76.3Fiscal year 2021Operating cash flow−115.7Capital expenditure−0.9Free cash flow−116.6Fiscal year 2022Operating cash flow−79.4Capital expenditure−0.9Free cash flow−80.3Fiscal year 2023Operating cash flow−79.0Capital expenditure−0.0Free cash flow−79.0Fiscal year 2024Operating cash flow−80.7Capital expenditure−0.1Free cash flow−80.9Fiscal year 2025Operating cash flow−82.5
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −46.8 −74.3 −115.7 −79.4 −79.0 −80.7 −82.5
Capital expenditure −2.8 −2.1 −0.9 −0.9 −0.0 −0.1 n/a
Free cash flow −49.6 −76.3 −116.6 −80.3 −79.0 −80.9 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash69.6Shareholders’ equity−64.9Fiscal year 2020Cash220.4Shareholders’ equity220.0Fiscal year 2021Cash186.8Shareholders’ equity184.7Fiscal year 2022Cash81.3Shareholders’ equity103.9Fiscal year 2023Cash135.7Shareholders’ equity92.1Fiscal year 2024Cash37.0Shareholders’ equity−29.0Fiscal year 2025Cash18.3Shareholders’ equity53.5
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 69.6 220.4 186.8 81.3 135.7 37.0 18.3
Shareholders’ equity −64.9 220.0 184.7 103.9 92.1 −29.0 53.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
n/a 0.0 0.0 0.0 6.2 3.6 2.2
Growth −41.7% −39.5%
44.0 79.9 104.2 85.1 73.0 70.3 69.5
10.0 17.9 28.5 26.4 30.6 22.8 20.7
−54.0 −97.8 −128.3 −97.6 −88.1 −89.2 −88.0
Growth
−52.2 −108.4 −128.2 −95.9 −86.9 −130.9 −23.9
0.1 0.2 0.1 0.1 0.8 0.3 0.3
−52.3 −108.5 −128.3 −96.0 −87.7 −131.2 −24.2
Growth
Per share
n/a n/a n/a −2.25 −34.20 −20.94 −2.45
n/a n/a n/a −2.25 −34.20 −20.94 −2.45
Growth
n/a n/a n/a 42.7 2.6 6.3 9.9
n/a n/a n/a 42.7 2.6 6.3 9.9
Growth −94.0% +144.4% +57.8%

† The diluted share count jumps at 2023 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.